Loading...
menu
Search
Features
Markets
News
Resources
Pricing
Home
ETF
PTHS
PTHS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
Latest PTHS ETF News Today | Earnings, Events & Price Alerts
PTHS News
Wall Street Analysts Adjust Ratings
4d ago
Benzinga
Horizon Technology Finance Provides $50 Million Loan Facility to Pelthos Therapeutics
Jan 15 2026
Newsfilter
Pelthos Therapeutics Secures $30 Million Financing to Accelerate ZELSUVMI Commercialization
Jan 13 2026
Globenewswire
Pelthos Appoints Andrew J. Einhorn to Board, Enhancing Financial Management
Dec 23 2025
Globenewswire
Pelthos Launches ZELSUVMI, First FDA-Approved At-Home Treatment for Molluscum Contagiosum
Dec 04 2025
Globenewswire
Linde Analyst Starts Coverage Optimistically; Check Out the Top 5 Initiations for Wednesday
Dec 03 2025
Benzinga
Pelthos Therapeutics Purchases Xepi® (ozenoxacin) Cream, 1%, and Reveals $18 Million Private Convertible Notes Funding
Nov 07 2025
Newsfilter
EXCLUSIVE: Pelthos Acquires Antimicrobial Drug Rights and Raises $18 Million for Commercial Launch Support
Nov 07 2025
Benzinga
Pelthos Obtains US Rights for Xepi and Secures $18 Million in Funding
Nov 07 2025
NASDAQ.COM
Pelthos Therapeutics Set to Attend Investor Conferences This September
Sep 08 2025
Newsfilter
Show More News
